US-based digital contract research organisation (dCRO) Clinipace Worldwide has signed a preferred-provider agreement under which it will manage several development programmes for Karyopharm Therapeutics, a clinical-stage company developing novel drugs for cancer and other major diseases.
As part of a long-term strategic partnership, Clinipace expects to manage “numerous” study starts on Karyopharm’s behalf during 2014. The clinical programmes in question take in oncology, wound healing and other conditions.
Based in Natick, Massachusetts, Karyopharm focuses on the discovery and development of first-in-class therapies directed against nuclear-transport targets.
The company’s Selective Inhibitors of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (CRM1).
Tailored therapies
“As tailored therapies such as those Karyopharm have under development become more prominent, drug developers must find increasingly innovative ways to help bring their products to market in the most effective and efficient manner,” commented Jeff Williams, co-founder and chief executive officer of Clinipace Worldwide.
Working with a technology-enabled dCRO gives Clinipace’s clients “a significant level of information-sharing that helps increase collaboration, improves data quality, and reduces their overall development costs,” Williams added.
